Zydus receives tentative approval from the USFDA for Sitagliptin and Metformin Hydrochloride Extended-Release Tablets

Deepthi | Myequity news | Date : 14-03-2019 14:43:00 IST

Zydus Cadila has received the tentative approval from the USFDA to market Sitagliptin and Metformin Hydrochloride Extended—ReleaseTablets, (USRLD JANUMET®XR), 50 mg / 500 mg, 50 mg / 1,000 mg and 100 mg / 1,000 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

It contains two oral antidiabetic medications used in the management of type 2 diabetes-Sitagliptin and metformin hydrochloride extended—release.

More from Myequity